Browsing Tag
Attruby
3 posts
Ionis Pharmaceuticals (IONS) drops 21% as Wainua Phase 3 ATTR-CM trial fails, Alnylam Amvuttra and BridgeBio Attruby emerge as clear beneficiaries
Ionis (IONS) drops 21% as Wainua Phase 3 ATTR-CM trial fails primary endpoint. Peak sales cut to $4B. Alnylam and BridgeBio benefit from the reset.
BridgeBio raises $1bn in preferred equity to fund rare disease product launches
BridgeBio’s $1 billion preferred equity raise strengthens BBIO’s balance sheet as Attruby grows and three rare disease launches approach.
BridgeBio Pharma weighs $1bn KKR, Sixth Street preferred equity deal as launch costs rise
BridgeBio Pharma may be preparing its balance sheet for three potential product launches, but the value of a $1 billion preferred equity deal will depend heavily on its undisclosed dividend, conversion and redemption terms.